Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma.

Medical Oncology
Alba FiorentinoVincenzo Fusco

Abstract

To assess the role of comorbidity on outcome in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant Temozolomide, patients over 65 years with glioblastoma, who underwent surgical resection or biopsy and radiochemotherapy, were evaluated. The Adjusted-Age Charlson Comorbidity Index and the Adult Comorbidity Evaluation-27 were used to assess comorbidity. From April 2005 to January 2011, 35 patients (median age 72 years) were treated in our Institution. Thirteen patients had a Charlson score more than 3, while, according to the Adult Comorbidity Evaluation-27, 21 patients had mild or severe comorbid conditions. Patients with low Charlson comorbidity score experienced a longer survival time than those with higher score (22 vs. 10 months, respectively). The Adjusted-Age Charlson Comorbidity Index influenced survival at univariate and multivariate analysis (p = 0.004, p = 0.001, respectively). No comorbidity index was a predictor for progression-free survival. Our data suggested that the association of radiotherapy with TMZ was safe and effective. Perhaps, the comorbidity assessment could be an appropriate tool in the treatment decision for elderly patients with glioblastoma.

References

Sep 1, 1996·Annals of Epidemiology·R YancikB K Edwards
Jan 11, 2001·The New England Journal of Medicine·L M DeAngelis
May 27, 2004·JAMA : the Journal of the American Medical Association·Jay F PiccirilloEdward L Spitznagel
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 13, 2007·The New England Journal of Medicine·Florence Keime-GuibertUNKNOWN Association of French-Speaking Neuro-Oncologists
Oct 30, 2007·Neurologic Clinics·James L FisherJoseph L Wiemels
Jan 16, 2009·Critical Reviews in Oncology/hematology·Jaime Gomez-Millan
Jun 30, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Neil KopekMorten Høyer
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kerri M Clough-GorrRebecca A Silliman
Sep 21, 2010·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Johanna GersteinClaus Rödel
Apr 28, 2011·Cancer·Timothy J DaskivichMark S Litwin
Jun 10, 2011·Current Treatment Options in Oncology·Susannah Yovino, Stuart A Grossman
Nov 15, 2011·International Journal of Radiation Oncology, Biology, Physics·Giuseppe MinnitiRiccardo Maurizi Enrici
Sep 19, 2012·La Radiologia medica·C ChiumentoV Fusco

❮ Previous
Next ❯

Citations

Jan 30, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A FiorentinoV Fusco
Feb 23, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A ValencianoP C Lara
Jul 24, 2014·CNS Oncology·Alba FiorentinoSilvia Chiesa
Jul 24, 2014·CNS Oncology·Florian Stockhammer
Jan 30, 2014·Journal of Geriatric Oncology·Luciola de Barros PontesSuzana Maria Fleury Malheiros
May 6, 2014·Neuro-oncology·Luc BauchetLuc Taillandier
Dec 20, 2013·Clinical Interventions in Aging·Emeline TabouretFrederique Rousseau
Aug 19, 2015·International Journal of Radiation Oncology, Biology, Physics·Niccolò Giaj LevraFilippo Alongi
Feb 26, 2015·Journal of Cancer Research and Clinical Oncology·Alba FiorentinoFilippo Alongi
Aug 1, 2012·The Lancet Oncology·Alba FiorentinoVincenzo Fusco
Jun 30, 2016·International Journal of Radiation Oncology, Biology, Physics·Filippo Alongi, Alba Fiorentino
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alba FiorentinoFilippo Alongi
Jan 19, 2019·Future Oncology·Veronica VillaniAndrea Pace
Oct 25, 2014·The Oncologist·Jaime Gállego Pérez-Larraya, Jean-Yves Delattre
Jan 15, 2014·Journal of Neuro-oncology·James L FisherStefan Lönn
Oct 15, 2013·Expert Review of Neurotherapeutics·Alba FiorentinoVincenzo Fusco
Feb 8, 2013·American Journal of Clinical Oncology·Alba FiorentinoVincenzo Valentini
Jul 30, 2017·Aging Clinical and Experimental Research·Alba FiorentinoFilippo Alongi
Sep 29, 2020·Expert Review of Anticancer Therapy·Alessia PellerinoRiccardo Soffietti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Alba FiorentinoVincenzo Fusco
Expert Review of Neurotherapeutics
Alba FiorentinoVincenzo Fusco
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Johanna GersteinClaus Rödel
© 2021 Meta ULC. All rights reserved